Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$908.5M
156M shares
52-week range
$4.45 – $13.88
20% from low
Sector
SERVICES-PREPACKAGED SOFTWARE
Exchange
NASDAQ
CS
Borrow rate
0.38%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $163.7M | $208.5M | $243.5M | $286.1M | $335.6M | $354.3M | $385.1M | $418.8M |
| Cost of revenue | $71.0M | $79.8M | $100.8M | $111.6M | $132.6M | $141.0M | $154.5M | $161.1M |
| Gross profit | $92.7M | $128.7M | $142.8M | $174.5M | $203.1M | $213.3M | $230.6M | $257.7M |
| Gross margin | 56.6% | 61.7% | 58.6% | 61.0% | 60.5% | 60.2% | 59.9% | 61.5% |
| R&D | $10.5M | $11.6M | $19.6M | $20.4M | $28.2M | $34.2M | $37.1M | $41.0M |
| Operating income | −$4.7M | $19.6M | −$24.4M | $13.6M | $32.5M | −$40.8M | −$1.7M | $21.0M |
| EBITDA | $32.3M | $60.4M | $17.9M | $58.6M | $89.0M | $23.8M | $72.4M | $83.9M |
| Net income | −$33.3M | −$8.9M | −$49.4M | −$13.3M | $14.7M | −$55.4M | −$12.1M | −$1.6M |
| Net margin | -20.3% | -4.3% | -20.3% | -4.6% | 4.4% | -15.6% | -3.1% | -0.4% |
| EPS (diluted) | -0.25 | -0.06 | -0.32 | -0.09 | 0.09 | -0.35 | -0.08 | -0.01 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $399M | $0.38 | $0.37–$0.40 | 6 |
| 2027 | $406M | $0.41 | $0.37–$0.43 | 6 |
| 2028 | $434M | $0.51 | $-1.21–$2.23 | 2 |
| 2029 | $457M | $0.55 | $0.54–$0.57 | 1 |
Forward consensus · source: Financial Modeling Prep
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
www.certara.comNo one on the platform currently holds CERT.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 354,500 | $2.0M |
| Bridgewater Associatesas of 2025-09-30 | 19,122 | $233.7K |
No one on the platform has traded CERT yet.
| $1.9B |
| — |
| PGNYProgyny, Inc. | $28.86 | +1.23% | $2.3B | — |
| QDELQuidelOrtho Corporation | $18.23 | +32.20% | $1.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Leerink thinks $CERT stock is way too cheap. It's still very profitable with strong long-term growth ahead. Today's purchase of rival $SLP at a ~90% premium to Certara's value highlights how undervalued it is.
View on StockTwits ↗$CERT Share Price: $5.14 Contract Selected: Nov 20, 2026 $5 Calls Buy Zone: $0.77 – $0.95 Target Zone: $1.31 – $1.60 Potential Upside: 62% ROI Time to Expiration: 161 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$LEXX Look at this monthly MACD and RSI chart for LEXX in this image. If I told you the most explosive fundamental chapter in this company's history was just around the corner, the technicals would back it up. We are looking at a classic, long-term macro trend reversal. The monthly MACD momentum histogram has flipped positive, and the signal lines are curling up from deep underwater after a multi-year base. Meanwhile, the RSI is quietly coiling right around the 40 line, building a massive energy spring. Once this macro accumulation phase snaps and price finally catches up to the momentum shift, we are looking at a powerful, multi-year breakout. Patience pays. 💰 $HYMC $CERT $GME $AMC
View on StockTwits ↗https://marketbeat.com/a/8698983/ $CERT Certara Outlines AI Push, Cost Cuts and New Growth Engines at Jefferies Conference
View on StockTwits ↗$CERT Doesn't look like trash to me small profits but green is good 🫡
View on StockTwits ↗Wall St is expecting 0.10 EPS for $CERT Q2 [Reporting 08/11 BMO] http://www.estimize.com/intro/cert?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗$CERT https://anachart.com/wp-content/uploads/2026/05/1778598097_soc-img.jpg
View on StockTwits ↗https://marketbeat.com/a/8648245/ $CERT Certara Q1 Earnings Call Highlights
View on StockTwits ↗https://www.marketbeat.com/earnings/reports/2026-5-11-certara-inc-stock/ $CERT Certara Earnings Transcript
View on StockTwits ↗$CERT $MOS $DOLE PRE-MARKET MOVERS: Currently Higher After Earnings: - Monday.com (MNDY) up 17.8% - Kodiak Gas Services (KGS) up 10.6% - Townsquare Media (TSQ) up 4.4% - Fox Corp. (FOXA) up 4.2% - Seadrill (SDRL) up 4.4% - Barrick Mining (B) up 4.0% - Circle Internet (CRCL) up 2.1% Currently Also Higher: - Moderna (MRNA) up 8.3% after a U.S. citizen tested positive for the Andes strain of hantavirus Currently Lower After Earnings: - Certara (CERT) down 8.1% - Mosaic (MOS) down 5.3% - Dole (DOLE) down 0.8% .
View on StockTwits ↗$CERT (-7.9% pre) Certara (Nasdaq: CERT) posts Q1 2026 loss, sells medical writing business https://ooc.bz/l/101768
View on StockTwits ↗$CERT printed Q1 overnight and the market's response is a 7.8% premarket fade to 5.82 on a whopping 77k shares. that's 0.03x avg vol, which is basically me, you, and three algos voting on the print before sunrise. stock's already -33% YTD and 58% off the highs so it's not like anyone's defending a trophy here. honest question, is this name even on anyone's radar anymore or did it quietly become a SMID-cap pharma services orphan? what hit overnight: https://tapeboard.com/chart/CERT?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=cert-pm-dn-news
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Trading at 2.6× sales vs its 8.1× historical median P/S.
Fair value ≈ $19.92 · price $6.36 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.